Abstract
Purpose
Beagle dogs are used to study oral pharmacokinetics and guide development of drug formulations for human use. Since mechanistic insight into species differences is needed to translate findings in this species to human, abundances of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) drug metabolizing enzymes have been quantified in dog liver and intestine.
Methods
Abundances of enzymes were measured in Beagle dog intestine and liver using selected reaction monitoring mass spectrometry.
Results
Seven and two CYPs were present in the liver and intestine, respectively. CYP3A12 was the most abundant CYP in both tissues. Seven UGT enzymes were quantified in the liver and seven in the intestine although UGT1A11 and UGT1A9 were present only in the intestine and UGT1A7 and UGT2B31 were found only in the liver. UGT1A11 and UGT1A2 were the most abundant UGTs in the intestine and UGT2B31 was the most abundant UGT in the liver. Summed abundance of UGT enzymes was similar to the sum of CYP enzymes in the liver whereas intestinal UGTs were up to four times more abundant than CYPs. The estimated coefficients of variation of abundance estimates in the livers of 14 donors were separated into biological and technical components which ranged from 14 to 49% and 20 to 39%, respectively.
Conclusions
Abundances of canine CYP enzymes in liver and intestine have been confirmed in a larger number of dogs and UGT abundances have been quantified for the first time. The biological variability in hepatic CYPs and UGTs has also been estimated.
Similar content being viewed by others
References
Sakamoto A, Matsumaru T, Ishiguro N, et al. Reliability and robustness of simultaneous absolute quantification of drug transporters, cytochrome P450 enzymes, and Udp-glucuronosyltransferases in human liver tissue by multiplexed MRM/selected reaction monitoring mode tandem mass spectrometry with nano-liquid chromatography. J Pharm Sci. 2011;100:4037–43.
Miliotis T, Ali L, Palm JE, et al. Development of a Highly Sensitive Method using LC-MRM to Quantify Membrane P-glycoprotein in Biological Matrices and Relationship to Transport Function. Drug Metab Dispos. 2011;39:2440–9.
Harbourt DE, Fallon JK, Ito S, et al. Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography–tandem mass spectrometry. Anal Chem. 2011;84:98–105.
Harwood MD, Neuhoff S, Carlson GL, Warhurst G, Rostami-Hodjegan A. Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. Biopharm Drug Dispos. 2013;34:2–28.
Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev. 2007;6:140–8.
Cubitt HE, Yeo KR, Howgate EM, Rostami-Hodjegan A, Barter ZE. Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica. 2011;41:623–38.
Barter ZE, Tucker GT, Rowland-Yeo K. Differences in cytochrome p450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2013;52:1085–100.
Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. Blood–brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther. 2011;339:579–88.
Heikkinen AT, Fowler S, Gray L, et al. In vitro to in vivo extrapolation and physiologically based modeling of cytochrome p450 mediated metabolism in beagle dog gut wall and liver. Mol Pharm. 2013;10:1388–99.
Prasad B, Evers R, Gupta A, et al. Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos. 2014;42:78–88.
Jones HM, Parrott N, Jorga K, Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet. 2006;45:511–42.
Rowland M, Peck C, Tucker G. Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science. Annu Rev Pharmacol Toxicol. 2011;51:45–73.
Garren KW, Rahim S, Marsh K, Morris JB. Bioavailability of generic ritonavir and Lopinavir/ritonavir tablet products in a dog model. J Pharm Sci. 2010;99:626–31.
Paulson SK, Vaughn MB, Jessen SM, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther. 2001;297:638–45.
Xia B, Heimbach T, Lin TH, et al. Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound. AAPS PharmSciTech. 2013;14:1255–66.
Kuentz M, Nick S, Parrott N, Röthlisberger D. A strategy for preclinical formulation development using GastroPlus™ as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci. 2006;27:91–9.
Kesisoglou F. Use of preclinical dog studies and absorption modeling to facilitate late stage formulation bridging for a BCS II drug candidate. AAPS PharmSciTech. 2013.
Dressman JB. Comparison of canine and human gastrointestinal physiology. Pharm Res. 1986;3:123–31.
Lui CY, Amidon GL, Berardi RR, et al. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci. 1986;75:271–4.
Martinez MN, Papich MG. Factors influencing the gastric residence of dosage forms in dogs. J Pharm Sci. 2009;98:844–60.
Soars MG, Riley RJ, Findlay KAB, Coffey MJ, Burchell B. Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos. 2001;29:121–6.
Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in caco-2 cells. Drug Metab Dispos. 1996;24:634–42.
Arndt M, Chokshi H, Tang K, et al. Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state. Eur J Pharm Biopharm. 2013;84:633–41.
Heikkinen AT, Friedlein A, Lamerz J, et al. Mass spectrometry-based quantification of CYP enzymes to establish in vitro - in vivo scaling factors for intestinal and hepatic metabolism in beagle Dog. Pharm Res. 2012;29:1832–42.
Hakooz N, Ito K, Rawden H, et al. Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res. 2006;23:533–9.
Martinez MN, Antonovic L, Court M, et al. Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metab Rev. 2013;45:218–30.
Shou M, Norcross R, Sandig G, et al. Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450. Drug Metab Dispos. 2003;31:1161–9.
Mise M, Yadera S, Matsuda M, et al. Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug Metab Dispos. 2004;32:240–5.
Zhou D, Linnenbach AJ, Liu R, et al. Expression and characterization of dog cytochrome P450 2A13 and 2A25 in baculovirus-infected insect cells. Drug Metab Dispos. 2010;38:1015–8.
Locuson CW, Ethell BT, Voice M, Lee D, Feenstra KL. Evaluation of escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase. Drug Metab Dispos. 2009;37:457–61.
Rahikainen T, Häkkinen MR, Finel M, Pasanen M, Juvonen RO. A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes. Xenobiotica. 2013.
Tenmizu D, Endo Y, Noguchi K, Kamimura H. Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion. Xenobiotica. 2004;34:835–46.
Roussel F, Duignan DB, Lawton MP, et al. Expression and characterization of canine cytochrome P450 2D15. Arch Biochem Biophys. 1998;357:27–36.
Li C, Wu Q. Adaptive evolution of multiple-variable exons and structural diversity of drug-metabolizing enzymes. BMC Evol Biol. 2007;7:69.
Soars MG, Fettes M, O'Sullivan AC, et al. Cloning and characterisation of the first drug-metabolising canine UDP-glucuronosyltransferase of the 2B subfamily. Biochem Pharmacol. 2003;65:1251–9.
Soars MG, Smith DJ, Riley RJ, Burchell B. Cloning and characterization of a canine UDP-glucuronosyltransferase. Arch Biochem Biophys. 2001;391:218–24.
MacLean B, Tomazela DM, Shulman N, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26:966–8.
Röst H, Malmström L, Aebersold R. A computational tool to detect and avoid redundancy in selected reaction monitoring. Mol Cell Proteomics : MCP. 2012;11:540–9.
Mise M, Hashizume T, Matsumoto S, Terauchi Y, Fujii T. Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics. 2004;14:769–73.
Eguchi K, Nishibe Y, Baba T, Ohno K. Quantitation of cytochrome P450 enzymes (CYP1A1/2, 2B11, 2C21 and 3A12) in dog liver microsomes by enzyme-linked immunosorbent assay. Xenobiotica. 1996;26:755–63.
Nishibe Y, Wakabayashi M, Harauchi T, Ohno K. Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver. Xenobiotica. 1998;28:549–57.
Kyokawa Y, Nishibe Y, Wakabayashi M, et al. Induction of intestinal cytochrome P450 (CYP3A) by rifampicin in beagle dogs. Chem Biol Interact. 2001;134:291–305.
Sakamoto K, Kirita S, Baba T, et al. A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: purification, cDNA cloning, and enzyme characterization. Arch Biochem Biophys. 1995;319:372–82.
Mealey KL, Jabbes M, Spencer E, Akey JM. Differential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine. Xenobiotica. 2008;38:1305–12.
Haller S, Schuler F, Lazic SE, et al. Expression profiles of metabolic enzymes and drug transporters in the liver and along the intestine of beagle dogs. Drug Metab Dispos. 2012;40:1603–11.
Uchida T, Komori M, Kitada M, Kamataki T. Isolation of cDNAs coding for three different forms of liver microsomal cytochrome P-450 from polychlorinated biphenyl-treated beagle dogs. Mol Pharmacol. 1990;38:644–51.
Bock KW, Bock KW, Bock-Hennig BS, et al. Tissue-specific regulation of canine intestinal and hepatic phenol and morphine UDP-glucuronosyltransferases by β-naphthoflavone in comparison with humans. Biochem Pharmacol. 2002;63:1683–90.
Nishimuta H, Sato K, Yabuki M, Komuro S. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug Metab Pharmacokinet. 2011.
Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos. 2010;38:1147–58.
Heikkinen AT, Baneyx G, Caruso A, Parrott N. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – an evaluation and case study using GastroPlus™. Eur J Pharm Sci. 2012;47:375–86.
Galetin A, Houston JB. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther. 2006;318:1220–9.
Froy O. Cytochrome P450 and the biological clock in mammals. Curr Drug Metab. 2009;10:104–15.
Smith R, Jones RD, Ballard PG, Griffiths HH. Determination of microsome and hepatocyte scaling factors for in vitro/in vivo extrapolation in the rat and dog. Xenobiotica. 2008;38:1386–98.
Bäärnhielm C, Dahlbäck H, Skånberg I. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol Toxicol. 1986;59:113–22.
Kamiie J, Ohtsuki S, Iwase R, et al. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res. 2008;25:1469–83.
Ohtsuki S, Schaefer O, Kawakami H, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2012;40:83–92.
Fallon JK, Neubert H, Hyland R, Goosen TC, Smith PC. Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. J Proteome Res. 2013;12:4402–13.
Achour B, Russell MR, Barber J, Rostami-Hodjegan A. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5’-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos. 2014;42:500–10.
Shuford CM, Sederoff RR, Chiang VL, Muddiman DC. Peptide production and decay rates affect the quantitative accuracy of protein cleavage isotope dilution mass spectrometry (PC-IDMS). Mol Cell Proteomics. 2012;11:814–23.
Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008;4:222.
Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A. 2003;100:6940–5.
Kawakami H, Ohtsuki S, Kamiie J, et al. Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J Pharm Sci. 2010;100:341–52.
Percy AJ, Chambers AG, Yang J, Hardie DB, Borchers C.H. Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. Biochim Biophys Acta .2013.
Campbell J, Rezai T, Prakash A, et al. Evaluation of absolute peptide quantitation strategies using selected reaction monitoring. Proteomics. 2011;11:1148–52.
Langenfeld E, Zanger UM, Jung K, Meyer HE, Marcus K. Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics. 2009;9:2313–23.
Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica. 2004;34:151–78.
Chen Y, Liu L, Nguyen K, Fretland AJ. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450. Drug Metab Dispos. 2011;39:373–82.
Ohno S, Nakajin S. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos. 2009;37:32–40.
Meech R, Miners JO, Lewis BC, Mackenzie PI. The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily. Pharmacol Ther. 2012;134:200–18.
Acknowledgments And Disclosures
This work was funded by Roche Postdoc Fellowship (RPF) program. The authors gratefully acknowledge: Zheng Yang (Bristol-Myers Squibb) for kind offering of labs and organisation of placement for intestinal microsome preparation; Mary Obermeier (Bristol-Myers Squibb) for assistance in the lab during intestinal microsome preparation; Laura Singer, Heather Martin, David Wellington and Claudia Suenderhauf (all Roche) for contributions on dog tissue collection and shipment; Martin Ebeling and Marco Berrera (Roche) for compiling the dog protein database; Peter Jakob (Roche) for sample preparation for MS experiments; Hannele Jaatinen, Pirjo Hänninen and Virpi Koponen (all University of Eastern Finland) for support in liver sample processing and characterization.
Supporting Information
Supplementary data is provided in data supplements available in electronic form: Illustrative figures of CYP and UGT enzyme abundance and activity, SRM assay parameters and study-to-study comparison of CYP quantitation results, and CYP and UGT abundance in individual samples.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heikkinen, A.T., Friedlein, A., Matondo, M. et al. Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine. Pharm Res 32, 74–90 (2015). https://doi.org/10.1007/s11095-014-1446-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-014-1446-8